Pipeline

Our Pipeline is comprised of Biologics, including the proprietary BEAT® MultispecificsTM platform, and one Cbl-b inhibitor small molecule targeting the spectrum of hematological cancers and solid tumors. If you are interested in exploring a partnership, Contact us.

Oncology

Diversity of Immune Cell Engagement and Indications across Hematologic and Solid Tumors

ASSETS DESCRIPTION INDICATION
CLINICAL ASSETS
PRECLINICAL PHASE 1 PHASE 2 PHASE 3
STATUS

BCMA x CD38 x CD3 TREAT ™
Trispecific T-Cell Engager

Multiple Myeloma
NCT05862012

PHASE 1
ORPHAN DRUG

GRC 65327

Cbl-b Inhibitor Small Molecule

Solid Tumors

PRECLINICAL
CANDIDATES

ISB 2301

IMMUNITE™

NK-Cell Engager

Solid Tumors

DISCOVERY

PRODUCTS

COMPOUND

CLINICAL ASSETS

TARGET
BCMA x CD38 x CD3 TREAT ™
trispecific T-Cell Engager

INDICATION
Multiple Myeloma

PHASE

NCT05862012

STATUS : 
PHASE 1 ORPHAN DRUG

PRODUCTS

COMPOUND
CLINICAL ASSETS
GRC 65327

TARGET
Cbl-b Inhibitor Small Molecule

INDICATION
Solid Tumors

PHASE

STATUS :
PRE-CLINICAL

PRODUCTS

COMPOUND
CANDIDATES
ISB 2301

TARGET
IMMUNITE™
NK-Cell Engager

INDICATION
Solid Tumors

PHASE

STATUS :
DISCOVERY

ISB 2001 is first TREATTM Trispecific Antibody for
Relapsed/Refractory Multiple Myeloma

KEY ATTRIBUTES
  • BCMA and CD38 are expressed on the surface of multiple myeloma cells 
and are clinically validated targets.
  • ISB 2001 combines three proprietary Fab arms binding to CD3 on T-cells, and to BCMA and CD38 on myeloma cells.
  • In vitro studies showed increased killing potency of tumor cells compared to all tested antibodies, including currently approved and investigational multiple myeloma therapies.
  • In vivo studies in multiple myeloma models also show superior potency relative to antibodies for the treatment of multiple myeloma.
  • ISB 2001 redirects CD3+ T lymphocytes to kill tumor cells expressing from low 

    to high levels of both BCMA and CD38.
  • With two different tumor-associated antigens, ISB 2001 is expected to be more resistant to antigen escape associated with treatment of MM patients
    .
  • CLINICAL DATA
    Clinical Data from part I (dose escalation) of the TRIgnite-1 study were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2025  (Link). The results demonstrated high overall response rates, with deep and durable responses in heavily pretreated patients with Relapsed/Refractory Multiple Myeloma – regardless of prior exposure to T-cell engagers (TCE) or CART-cell therapies. The safety profile was favorable, with most side effects being low-grade and manageable.
isb2001_new
TREAT™: Trispecific Engagement by Antibodies based on the TCR MHC: Major histocompatibility complex, CDC: Complement-Dependent Cytotoxicity ADCC: Antibody-Dependent Cell-mediated Cytotoxicity

GRC 65327 A Novel Small Molecule
Selective Oral Cbl-b Inhibitor Immunotherapeutics

  • Selective, small molecule, orally available, Cbl-b inhibitor, phase I-ready for solid tumor indications.

  • Demonstrated nM Cbl-b activity, >20-fold selectivity, potentiation of IL-2 and IFN-γ and T cells proliferation.

  • Significant tumor growth inhibition as a monotherapy and in combination with anti-PD1, while also inducing durable complete responses associated with memory immune responses.

  • In a 1-month GLP monkey toxicology study, an increased T cells activation and infiltration was observed in mesenteric lymph nodes (a tissue immune response) at very low exposures of AUC ~1500 ng.h/mL and above.

  • IND submission to DCGI completed in October 2024

For collaborations, please contact us here.

Inflammation and Autoimmune Disease

The autoimmune disease assets have been out-licensed to enable greater focus on oncology. Explore the pipeline chart below to learn more and Contact Us  for additional information.

Autoimmune Disease

PRODUCTS
Telazorlimab (and ISB 830-X8)

DESCRIPTION
OX40 antagonist
Monoclonal Antibody

Atopic Dermatitis*​

Alliance Partner

astria

$320 million for upfront payment, development, regulatory and sales milestone payments,
plus tiered royalties on global sales

STATUS
SUCCESSFUL
PHASE 2B*

PRODUCTS
ISB 830-X8/STR-310

DESCRIPTION
OX40 antagonist
Monoclonal Antibody

Atopic Dermatitis*​

Alliance Partner

astria

$320 million for upfront payment, development, regulatory and sales milestone payments,
plus tiered royalties on global sales

STATUS
PRE-CLINICAL

Asset/ MOA
ISB 880 / ALM27134

STATUS
IL-1RAP antagonist
Monoclonal Antibody

Hidradenitis Suppurativa

Alliance Partner

almirali

€20.8 million for upfront payment. Plus development, regulatory and sales milestone payments,
and tiered royalties on global sales

PRODUCTS DESCRIPTION
PRECLINICAL PHASE 1 PHASE 2 PHASE 3
STATUS

Licensed to

Astri

$320 million for upfront payment, development, regulatory and sales milestone payments,
plus tiered royalties on global sales

Telazorlimab

ISB 830-X8/STR-310

Atopic Dermatitis*​


SUCCESSFUL
PHASE 2B*

ISB 830-X8/(STR-0310)

OX40 antagonist
Monoclonal Antibody

PHASE 1a

Licensed to

almirall

€20.8 million for upfront payment. Plus development, regulatory and sales milestone payments,
and tiered royalties on global sales

ISB 880/ALM27134

IL-1RAP antagonist
Monoclonal Antibody

Hidradenitis Suppurativa

PHASE 1

*A US IND for rheumatoid arthritis and other autoimmune indications is active.